At present, the diagnosis of Parkinson’s disease is mainly based on clinical standards, but the sensitivity of clinical standards is often limited before most dopaminergic neurons are lost. Recently, in a research report published in Nature Aging titled “DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease”, scientists from institutions such as the Caroline College in Sweden found through research that, the levels of the…